SMFM 咨询系列第49号:剖宫产瘢痕妊娠
剖宫产瘢痕妊娠是早孕期胚胎种植于既往剖宫产瘢痕处的并发症,因诊断困难且最佳治疗不确定,严重母体并发症风险高。超声是主要诊断手段。SMFM 建议:不建议期待治疗;手术可选切除(经阴道或腹腔镜)或超声引导下负压吸引,避免单纯锐性刮宫;药物治疗建议宫腔内甲氨蝶呤(可联合其他方式),不建议单用全身甲氨蝶呤;期待治疗并继续妊娠者建议 34 0/7–35 6/7 周重复剖宫产;应告知再次妊娠风险并指导有效避孕。
要点
- 不建议对剖宫产瘢痕妊娠进行期待治疗(GRADE 1B)。
- 手术可选切除或超声引导下负压吸引,避免单纯锐性刮宫(GRADE 2C)。
- 不建议单用全身甲氨蝶呤治疗(GRADE 1C)。
核心结论
- 剖宫产瘢痕妊娠严重母体并发症风险高,不建议期待治疗,应积极干预并告知再次妊娠风险与避孕。
研究设计与样本
- 本文为美国母胎医学会(SMFM)咨询系列第49号,针对剖宫产瘢痕妊娠的诊断与治疗提出推荐。
主要发现
- 超声是剖宫产瘢痕妊娠的主要诊断手段,但正确及时诊断可能困难。
- 手术、药物及微创治疗均有报道,但最佳治疗尚不明确。
- 拒绝治疗的女性应被告知严重并发症风险。
关键数值与推荐
- 不建议期待治疗剖宫产瘢痕妊娠(GRADE 1B)。
- 建议考虑手术切除(尽可能经阴道或腹腔镜)或超声引导下负压吸引,避免单纯锐性刮宫(GRADE 2C)。
- 建议宫腔内甲氨蝶呤治疗,可联合或不联合其他方式(GRADE 2C)。
- 不建议单用全身甲氨蝶呤治疗剖宫产瘢痕妊娠(GRADE 1C)。
- 期待治疗并继续妊娠者,建议在 34 0/7 至 35 6/7 周之间重复剖宫产(GRADE 1C)。
临床怎么用
- 对剖宫产瘢痕妊娠应避免期待治疗,根据情况选择手术切除或超声引导下负压吸引。
- 药物治疗可考虑宫腔内甲氨蝶呤,但不单用全身甲氨蝶呤。
- 期待治疗并继续妊娠者应在 34 0/7–35 6/7 周重复剖宫产,并做好避孕咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cesarean scar pregnancy is a complication in which an early pregnancy implants in the scar from a prior cesarean delivery. This condition presents a substantial risk for severe maternal morbidity because of challenges in securing a prompt diagnosis, as well as uncertainty regarding optimal treatment once identified. Ultrasound is the primary imaging modality for cesarean scar pregnancy diagnosis, although a correct and timely determination can be difficult. Surgical, medical, and minimally invasive therapies have been described for cesarean scar pregnancy management, but the optimal treatment is not known. Women who decline treatment of a cesarean scar pregnancy should be counseled regarding the risk for severe morbidity. The following are Society for Maternal-Fetal Medicine recommendations: We recommend against expectant management of cesarean scar pregnancy (GRADE 1B); we suggest operative resection (with transvaginal or laparoscopic approaches when possible) or ultrasound-guided vacuum aspiration be considered for surgical management of cesarean scar pregnancy and that sharp curettage alone be avoided (GRADE 2C); we suggest intragestational methotrexate for medical treatment of cesarean scar pregnancy, with or without other treatment modalities (GRADE 2C); we recommend that systemic methotrexate alone not be used to treat cesarean scar pregnancy (GRADE 1C); in women who choose expectant management and continuation of a cesarean scar pregnancy, we recommend repeat cesarean delivery between 34 0/7 and 35 6/7 weeks of gestation (GRADE 1C); we recommend that women with a cesarean scar pregnancy be advised of the risks of another pregnancy and counseled regarding effective contraceptive methods, including long-acting reversible contraception and permanent contraception (GRADE 1C).
引用
- Miller R, Timor-Tritsch IE, Gyamfi-Bannerman C, et al. Society for Maternal-Fetal Medicine (SMFM) Consult Series #49: Cesarean scar pregnancy. Am J Obstet Gynecol. 2020. PMID: 31972162. doi:10.1016/j.ajog.2020.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。